Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
US5399565A · kind A · utility
10Cited by
6References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 12, 1993 |
| Grant date | Mar 21, 1995 |
| Priority date | — |
| Expiry date | Nov 12, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Novel substituted pyrazolidinones have been found to exhibit significant binding to cholecystokinin (CCK) receptors and gastrin receptors in the brain and/or peripheral sites such as the pancreas, stomach, and ileum. The pyrazolidinones are CCK and gastrin receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders, central nervous system disorders and for appetite regulation in warm-blood vertebrates. Pharmaceutical formulations for such indications are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.